HomeCompareSGLJF vs ABBV

SGLJF vs ABBV: Dividend Comparison 2026

SGLJF yields 0.77% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGLJF wins by $1.53M in total portfolio value· pulled ahead in Year 7
10 years
SGLJF
SGLJF
● Live price
0.77%
Share price
$47.52
Annual div
$0.37
5Y div CAGR
98.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.63M
Annual income
$1,282,392.40
Full SGLJF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SGLJF vs ABBV

📍 SGLJF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGLJFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGLJF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGLJF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGLJF
Annual income on $10K today (after 15% tax)
$65.86/yr
After 10yr DRIP, annual income (after tax)
$1,090,033.54/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SGLJF beats the other by $1,068,977.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGLJF + ABBV for your $10,000?

SGLJF: 50%ABBV: 50%
100% ABBV50/50100% SGLJF
Portfolio after 10yr
$867.3K
Annual income
$653,582.08/yr
Blended yield
75.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGLJF
No analyst data
Altman Z
4.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGLJF buys
0
ABBV buys
0
No recent congressional trades found for SGLJF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGLJFABBV
Forward yield0.77%3.06%
Annual dividend / share$0.37$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR98.1%40.6%
Portfolio after 10y$1.63M$102.3K
Annual income after 10y$1,282,392.40$24,771.77
Total dividends collected$1.58M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGLJF vs ABBV ($10,000, DRIP)

YearSGLJF PortfolioSGLJF Income/yrABBV PortfolioABBV Income/yrGap
1$10,853$153.49$11,550$430.00$697.00ABBV
2$11,922$308.43$13,472$627.96$1.6KABBV
3$13,383$627.22$15,906$926.08$2.5KABBV
4$15,624$1,303.61$19,071$1,382.55$3.4KABBV
5$19,535$2,817.54$23,302$2,095.81$3.8KABBV
6$27,425$6,522.26$29,150$3,237.93$1.7KABBV
7← crossover$46,297$16,952.25$37,536$5,121.41+$8.8KSGLJF
8$102,520$52,982.86$50,079$8,338.38+$52.4KSGLJF
9$326,915$217,218.02$69,753$14,065.80+$257.2KSGLJF
10$1,632,191$1,282,392.40$102,337$24,771.77+$1.53MSGLJF

SGLJF vs ABBV: Complete Analysis 2026

SGLJFStock

Strauss Group Ltd., together with its subsidiaries, develops, manufactures, markets, and sells various food and beverage products in Israel, North America, Brazil, Europe, and internationally. The company operates through six segments: Health & Wellness; Fun & Indulgence; Israel Coffee; International Coffee; International Dips & Spreads; and Strauss Water. The Health & Wellness segment provides yogurts, dairy desserts, dairy-free tahini desserts, soft cheeses, flavored milk beverages, chilled salads, cut vegetables, fresh pasta products, cereal and granola bars, honey products, olive oils, fruit preserves, cooking sauces, lemon juices, and natural maple syrups. This segment also sells and distributes natural juices, butter spreads, and plant-based probiotic desserts. The Fun & Indulgence segment offers sweet snack bars, chocolate tablets, sweet spreads, candies, chewing gums, cakes and cookies, biscuits, wafers, and salty snacks. The Israel Coffee segment develops, manufactures, sells, markets, and distributes a range of coffee products, chocolate powders, and other drink powders; sells coffee beans; and retails coffee products. The International Coffee segment develops and manufactures various coffee products and powder drinks; markets and distributes coffee machines; and purchases and processes green coffee, corn products, cashew-based dairy substitutes and juice powders. The International Dips & Spreads segment manufactures, markets, and sells chilled dips and spreads under the Sabra, Obela, and Florentin brands. The Strauss Water segment also develops, manufactures, distributes, and sells filtration, purification, and carbonation systems for drinking water. The company was formerly known as Strauss-Elite Ltd. and changed its name to Strauss Group Ltd. in February 2007. Strauss Group Ltd. was incorporated in 1933 and is headquartered in Petah Tikva, Israel. Strauss Group Ltd. is a subsidiary of Strauss Holdings Ltd.

Full SGLJF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGLJF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGLJF vs SCHDSGLJF vs JEPISGLJF vs OSGLJF vs KOSGLJF vs MAINSGLJF vs JNJSGLJF vs MRKSGLJF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.